AI regulation

Sara Shanti, partner at Sheppard Mullin, discusses the intersection of healthcare and technology, how to establish trust and transparency within AI, and questions she receives pertaining to virtual therapy, particularly in mental health.

Brigid Bondoc, partner and life sciences attorney at Morrison Foerster, discusses government priorities pertaining to federal regulation of AI, where complications may arise, and concerns she has heard related to policy decisions.  

Jay Rughani, investment partner at a16z, discusses 2023 events, predictions for digital health funding in 2024 and proper AI regulation to avoid stifling innovation.

Thomas Hallisey, HANYS digital health strategy lead, discusses appropriate regulations on digital health at the state and federal levels and the need for continuous management as technology moves from automating healthcare to augmenting it.  

The American Medical Association uses “augmented intelligence,” not “artificial intelligence,” as the tech is meant to support, not replace, people, said Dr. Jesse Ehrenfeld, president of the AMA. Still, new regulatory paradigms are needed.

Dr. Michael Howell, Google's chief clinical officer, discusses what federal regulators should consider while configuring rules around AI use in healthcare and how the company ensures health equity within its medically tuned LLM, Med-PaLM.  

Dr. Michael Howell, chief clinical officer at Google, discusses Med-PaLM's evolution in 2023 and recommendations for regulators developing rules for AI use in healthcare.